Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Lapaquistat Acetate Alone or Combined With High-Dose Statin Therapy in Subjects With Hypercholesterolemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Woman of childbearing potential can not to be pregnant, lactating, not planning on becoming pregnant, and agree to use acceptable forms of contraception throughout the course of the study.~* Prior to Randomization, has a low-density lipoprotein cholesterol level mean greater than or equal to 3.37 mmol/L and less than or equal to 5.70 mmol/L.~* Prior to Randomization, has a mean triglyceride level less than or equal to 4.52 mmol/L (400 mg/dL).~* Has clinical laboratory evaluations including clinical chemistry, hematology, and urinalysis within the defined reference range.~* The subject had taken the highest recommended dose of a statin for at least 4 weeks prior to Visit 1.~Exclusion Criteria:~* Has an alanine aminotransferase or aspartate aminotransferase level of greater than 1.5 times the upper limit of normal, active liver disease or jaundice.~* Has a serum creatinine of greater than 133 μmol/L.~* Has a creatine kinase greater than 3 times the upper limit of normal.~* Has type 1 or 2 diabetes mellitus.~* Has a previous history of cancer that had been in remission for less than 5 years prior to the first dose of study medication.~* Has an endocrine disorder, such as Cushing syndrome, hyperthyroidism, or inappropriately treated hypothyroidism, affecting lipid metabolism.~* Has a history of myocardial infarction, angina pectoris, transient ischemic attacks, cerebrovascular accident, peripheral vascular disease, abdominal aortic aneurysm, coronary revascularization or multiple factors that conferred a 10-year risk for coronary heart disease greater than 20% based on Framingham risk scoring.~* Has a positive hepatitis B surface antigen, or antibody to hepatitis C virus, as determined by medical history and/or subject's verbal report.~* Has a positive human immunodeficiency virus status or was taking antiretroviral medications, as determined by medical history.~* Has exposure to lapaquistat acetate in other studies, was participating in another investigational study, or had participated in an investigational study within the past 30 days or, for drugs with a long half-life, within a period of less than 5 times the drug's half-life.~* The subject had a known hypersensitivity or history of adverse reaction to atorvastatin, simvastatin or rosuvastatin.~* Has a history or presence of clinically significant food allergy that would prevent adherence to the recommended diet.~* Has a known heterozygous or homozygous familial hypercholesterolemia or known Type III hyperlipoproteinemia (familial dysbetalipoproteinemia).~* Has fibromyalgia, myopathy, rhabdomyolysis or unexplained muscle pain.~* Has uncontrolled hypertension~* Has inflammatory bowel disease, any other malabsorption syndrome, or had gastric bypass or any other surgical procedure for weight loss.~* Is unwilling or unable, in the opinion of the investigator, to comply with the protocol or scheduled appointments.~* Has a history of drug abuse or a history of alcohol abuse within the past 2 years.~* Has any other serious disease or condition that might reduced life expectancy, impaired successful management according to the protocol, or make the participant an unsuitable candidate to receive study medication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lapaquistat Acetate 100 mg QD (Type: EXPERIMENTAL): (and stable statin therapy)
- Stable statin therapy (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).